⏳ Fetching live dividend data...
Home › Calculator › VERU Dividend Calculator 2026
Veru Inc. · NASDAQ
Price: $2.37 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in VERU → $176289663206.41M in 10 years · $14,673,824,327,914,758.00/month
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open VERU position with:
Real after-tax yield depends on where you live and how you hold VERU.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 84.39% | 81.59% | $8,439 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 71.73% | 68.93% | $7,173 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 67.51% | 64.71% | $6,751 / yr |
| 🇬🇧 UK ISA | 0% | 84.39% | 81.59% | $8,439 / yr |
| 🇬🇧 UK Taxable | 8.75% | 77.01% | 74.21% | $7,701 / yr |
| 🇨🇦 TFSA | 0% | 84.39% | 81.59% | $8,439 / yr |
| 🇨🇦 CA Taxable | 25% | 63.29% | 60.49% | $6,329 / yr |
| 🇦🇺 Super (pension) | 15% | 71.73% | 68.93% | $7,173 / yr |
| 🇦🇺 AU Taxable | 30% | 59.07% | 56.27% | $5,907 / yr |
| 🇩🇪 DE Taxable | 26.375% | 62.13% | 59.33% | $6,213 / yr |
| 🇫🇷 FR Taxable | 30% | 59.07% | 56.27% | $5,907 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
VERU pays quarterly — 4 times per year. Next ex-div: TBD.
How VERU compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VERU sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-05-04 | 604,000 | $2.25 | $1.36M | ||
| A-Award | 2026-05-04 | 164,000 | $2.25 | $369.0K | ||
| A-Award | 2026-05-04 | 102,000 | $2.25 | $229.5K | ||
| A-Award | 2026-05-04 | 97,000 | $2.25 | $218.3K | ||
| A-Award | 2026-05-04 | 100,000 | $2.25 | $225.0K | ||
| A-Award | 2026-05-04 | 104,000 | $2.25 | $234.0K | ||
| A-Award | 2026-05-04 | 160,000 | $2.25 | $360.0K | ||
| A-Award | 2026-05-04 | 160,000 | $2.25 | $360.0K | ||
| A-Award | 2025-12-05 | 27,000 | $2.49 | $67.2K | ||
| A-Award | 2025-12-05 | 3,000 | $2.49 | $7.5K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VERU dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →